Gilbert & Cook’s Gain Therapeutics GANX Stock Holding History

Gilbert & Cook’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-10,000	Closed	-$12.8K	–	221
2024 Q2	$12.8K	Buy	+10,000	New	+$26K	﹤0.01%	212

Other funds holding GANX

GAM

Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return

DCM

DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Gilbert & Cook's GANX Position: Q3 2024 in Review

Gilbert & Cook sold out of Gain Therapeutics (GANX) in Q3 2024, closing a stake of 10,000 shares — an estimated $12.8K sold.

Gilbert & Cook first reported a position in GANX in Q2 2024 and held it in 1 quarter. The position peaked at $12.8K in Q2 2024. 19 funds tracked by Wall St. Rank hold GANX as of Q3 2024.

Gilbert & Cook reported no remaining Gain Therapeutics position as of Q3 2024 after selling out during the quarter.
Gilbert & Cook sold 10,000 Gain Therapeutics shares in Q3 2024, an estimated $12.8K.
Gilbert & Cook first reported a position in Gain Therapeutics in Q2 2024 and held it in 1 quarter.
Gilbert & Cook's Gain Therapeutics position peaked at $12.8K in Q2 2024.
19 funds tracked by Wall St. Rank held Gain Therapeutics as of Q3 2024.

Based on Gilbert & Cook's 13F filing for Q3 2024, filed 7 Nov 2024.